{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:30:49Z","timestamp":1762972249608,"version":"3.45.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background &amp; aims<\/jats:title>\n                    <jats:p>Primary sclerosing cholangitis (PSC) is a rare chronic liver disease that impact quality of life (QoL). This study investigated the association between biomarkers of PSC disease severity and QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective study involving 80 participants with PSC at baseline and 55 at 1-year follow-up. QoL was assessed using patient reported outcomes (PROMs): RAND-SF36, SF6D and PSC-PRO. MRI-MRCP data was analysed using LiverMultiscan for iron-corrected liver T1 (cT1) and MRCP+ for the relative severity of intrahepatic biliary dilatations (RSIBD). Disease severity was also classified using FibroScan liver stiffness (LS), enhanced liver fibrosis (ELF), Mayo risk score (MRS), Amsterdam-Oxford model (AOM), alkaline phosphatase (ALP), presence of extrahepatic disease and dominant stricture (DS). Descriptive and regression analyses were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, more advanced PSC was associated with differences in PROMs, AOM\u2009&gt;\u20092, (PSC-PRO PSC symptoms, 5.181, p\u2009=\u20090.048), LS\u2009&gt;\u20099.6 kPa (SF-6D, \u22120.081, p\u2009=\u20090.027), cT1\u2009&gt;\u2009825ms (SF6D QoL, \u22120.161, p\u2009=\u20090.004; SF36 PCS, \u221210.595, p\u2009=\u20090.001; SF36 MCS, \u221210.726, p\u2009=\u20090.012), DS (PSC-PRO symptoms scores, 5.800, p\u2009=\u20090.025), RSIBD (SF-6D, \u22120.081, p\u2009=\u20090.016). During follow-up, increase in LS was associated with a reduction in QoL measured via SF-6D (\u22120.002, p\u2009&lt;\u20090.001), SF36 physical component summary (\u22120.246, p\u2009&lt;\u20090.001) and SF36 mental component summary (\u22120.171, p\u2009&lt;\u20090.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>QoL in PSC was associated with biomarkers of parenchymal liver fibrosis (LS, cT1), biliary disease (dominant strictures, RSIBD), and composite scores of disease severity (AOM). Increasing LS predicted further declines in QoL. Further research should explore MRCP+ metrics and their impact on QoL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0335642","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:27:36Z","timestamp":1762972056000},"page":"e0335642","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between non-invasive biomarkers and quality of life in Primary Sclerosing Cholangitis"],"prefix":"10.1371","volume":"20","author":[{"given":"Jingyu","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma L.","family":"Culver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9882-8874","authenticated-orcid":true,"given":"Michael","family":"Pavlides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-6730","authenticated-orcid":true,"given":"Jose","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"4","key":"pone.0335642.ref001","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/hep4.1860","article-title":"A quantitative magnetic resonance cholangiopancreatography metric of intrahepatic biliary dilatation severity detects high-risk primary sclerosing cholangitis","volume":"6","author":"EA Selvaraj","year":"2022","journal-title":"Hepatol Commun"},{"issue":"6","key":"pone.0335642.ref002","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2021.07.046","article-title":"Defining primary sclerosing cholangitis: results from an international primary sclerosing cholangitis study group consensus process","volume":"161","author":"CY Ponsioen","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"pone.0335642.ref003","first-page":"589","article-title":"An overview of recent treatment options for primary sclerosing cholangitis","volume":"36","author":"I Mousavere","year":"2023","journal-title":"Ann Gastroenterol"},{"issue":"8","key":"pone.0335642.ref004","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.08.039","article-title":"Epidemiology, natural history, and outcomes of primary sclerosing cholangitis: a systematic review of population-based studies","volume":"20","author":"PJ Trivedi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"pone.0335642.ref005","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A revised natural history model for primary sclerosing cholangitis","volume":"75","author":"WR Kim","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"pone.0335642.ref006","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","article-title":"A novel prognostic model for transplant-free survival in primary sclerosing cholangitis","volume":"67","author":"EM de Vries","year":"2018","journal-title":"Gut"},{"issue":"40","key":"pone.0335642.ref007","doi-asserted-by":"crossref","first-page":"14626","DOI":"10.3748\/wjg.v20.i40.14626","article-title":"Non-invasive diagnosis of alcoholic liver disease","volume":"20","author":"S Mueller","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"1","key":"pone.0335642.ref008","first-page":"100","article-title":"Quality of life in primary sclerosing cholangitis: a systematic review","volume":"19","author":"E Marcus","year":"2021","journal-title":"HQLO"},{"issue":"7","key":"pone.0335642.ref009","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1007\/s00330-020-06728-6","article-title":"Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography","volume":"30","author":"M Tafur","year":"2020","journal-title":"Eur Radiol"},{"issue":"1","key":"pone.0335642.ref010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00261-016-0847-z","article-title":"Early Peribiliary hyperenhancement on MRI in patients with primary sclerosing cholangitis: significance and association with the mayo risk score","volume":"42","author":"JM Ni Mhuircheartaigh","year":"2017","journal-title":"Abdom Radiol (NY)"},{"issue":"5","key":"pone.0335642.ref011","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2019.06.012","article-title":"Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis","volume":"71","author":"JC Goet","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0335642.ref012","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.12.030","article-title":"Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis","volume":"146","author":"C Corpechot","year":"2014","journal-title":"Gastroenterology"},{"issue":"10","key":"pone.0335642.ref013","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/liv.13402","article-title":"Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study","volume":"37","author":"EMG de Vries","year":"2017","journal-title":"Liver Int"},{"issue":"2","key":"pone.0335642.ref014","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis","volume":"58","author":"S Al Mamari","year":"2013","journal-title":"J Hepatol"},{"issue":"5","key":"pone.0335642.ref015","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/hep.30479","article-title":"Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system","volume":"69","author":"EC Goode","year":"2019","journal-title":"Hepatology"},{"issue":"9","key":"pone.0335642.ref016","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/MEG.0b013e3283554bbf","article-title":"Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience","volume":"24","author":"MH Chapman","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"pone.0335642.ref017","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/hep.29664","article-title":"Development and validation of a primary sclerosing cholangitis\u2013specific patient\u2010reported outcomes instrument: the PSC PRO","volume":"68","author":"ZM Younossi","year":"2018","journal-title":"Hepatology"},{"key":"pone.0335642.ref018","volume-title":"SF-36 physical and mental health summary scales: a user\u2019s manual","author":"JE Ware","year":"1994"},{"key":"pone.0335642.ref019","author":"RAND","year":"2024"},{"issue":"2","key":"pone.0335642.ref020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"J Brazier","year":"2002","journal-title":"J Health Econ"},{"issue":"2","key":"pone.0335642.ref021","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1162\/0034653053970320","article-title":"Fixed-effects and related estimators for correlated random-coefficient and treatment-effect panel data models","volume":"87","author":"JM Wooldridge","year":"2005","journal-title":"Rev Econ Stat"},{"issue":"6","key":"pone.0335642.ref022","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2307\/1913827","article-title":"Specification tests in econometrics","volume":"46","author":"JA Hausman","year":"1978","journal-title":"Econometrica"},{"issue":"3","key":"pone.0335642.ref023","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"W-K Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"issue":"13","key":"pone.0335642.ref024","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.04.046","article-title":"Decreased quality of life is significantly associated with body composition in patients with nonalcoholic fatty liver disease","volume":"18","author":"N Samala","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"pone.0335642.ref025","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.3390\/nu15133018","article-title":"Impact of health related qol and mediterranean diet on liver fibrosis in patients with NAFLD","volume":"15","author":"N Perez-Diaz-Del-Campo","year":"2023","journal-title":"Nutrients"},{"issue":"12","key":"pone.0335642.ref026","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.04.018","article-title":"Health-related quality of life in patients with nonalcoholic fatty liver disease: a prospective multi-center UK study","volume":"21","author":"M Papatheodoridi","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"pone.0335642.ref027","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1185\/03007990902774765","article-title":"Optimal recall periods for patient-reported outcomes: challenges and potential solutions","volume":"25","author":"DE Stull","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"pone.0335642.ref028","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/hec.1351","article-title":"Impact of the recall period on measuring health utilities for acute events","volume":"17","author":"N Bansback","year":"2008","journal-title":"Health Econ"},{"issue":"3","key":"pone.0335642.ref029","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40271-022-00611-w","article-title":"Systematic review of the effect of a one-day versus seven-day recall duration on patient reported outcome measures (PROMs)","volume":"16","author":"T Peasgood","year":"2023","journal-title":"Patient"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:27:43Z","timestamp":1762972063000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335642"}},"subtitle":[],"editor":[{"given":"Olivier","family":"Barbier","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0335642","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}